[go: up one dir, main page]

MX2018002326A - Analogos novedosos de nucleosidos sustituidos en el anillo aromatico biciclico 6-6 para su uso como inhibidores de prmt5. - Google Patents

Analogos novedosos de nucleosidos sustituidos en el anillo aromatico biciclico 6-6 para su uso como inhibidores de prmt5.

Info

Publication number
MX2018002326A
MX2018002326A MX2018002326A MX2018002326A MX2018002326A MX 2018002326 A MX2018002326 A MX 2018002326A MX 2018002326 A MX2018002326 A MX 2018002326A MX 2018002326 A MX2018002326 A MX 2018002326A MX 2018002326 A MX2018002326 A MX 2018002326A
Authority
MX
Mexico
Prior art keywords
aromatic ring
nucleosids
replaced
prmt5 inhibitors
new analogs
Prior art date
Application number
MX2018002326A
Other languages
English (en)
Other versions
MX392554B (es
Inventor
Lieven Meerpoel
Ronaldus Arnodus Hendrika Joseph Gilissen
Gaston Stanislas Marcella Diels
Marcel Viellevoye
Johannes Wilhelmus John F Thuring
Wim Bert Griet Schepens
An Boeckx
Tongfei Wu
BREHMER Dirk
BEKE Lijs
Charles LAWSON Edward
Pande Vineet
Cornelis Bernardus Catharina Parade Marcus
Sun Weimei
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2018002326A publication Critical patent/MX2018002326A/es
Publication of MX392554B publication Critical patent/MX392554B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a análogos novedosos de nucleósidos sustituidos en el anillo aromático bicíclico 6-6 de Fórmula (I) (ver Fórmula) donde las variables tienen el significado definido en las reivindicaciones; los compuestos de acuerdo con la presente invención son útiles como inhibidores de PRMT5; la invención se refiere además a composiciones farmacéuticas que comprenden dichos compuestos como principio activo, así como también al uso de dichos compuestos como un medicamento.
MX2018002326A 2015-08-26 2016-08-25 Análogos novedosos de nucleósidos sustituidos en el anillo aromático bicíclico 6-6 para su uso como inhibidores de prmt5. MX392554B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562209941P 2015-08-26 2015-08-26
EP15184011 2015-09-07
US201662306233P 2016-03-10 2016-03-10
PCT/EP2016/070097 WO2017032840A1 (en) 2015-08-26 2016-08-25 Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors

Publications (2)

Publication Number Publication Date
MX2018002326A true MX2018002326A (es) 2018-04-11
MX392554B MX392554B (es) 2025-03-24

Family

ID=54065259

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018002326A MX392554B (es) 2015-08-26 2016-08-25 Análogos novedosos de nucleósidos sustituidos en el anillo aromático bicíclico 6-6 para su uso como inhibidores de prmt5.
MX2022005182A MX2022005182A (es) 2015-08-26 2018-02-23 Analogos novedosos de nucleosidos sustituidos en el anillo aromatico biciclico 6-6 para su uso como inhibidores de prmt5.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022005182A MX2022005182A (es) 2015-08-26 2018-02-23 Analogos novedosos de nucleosidos sustituidos en el anillo aromatico biciclico 6-6 para su uso como inhibidores de prmt5.

Country Status (35)

Country Link
US (4) US10653711B2 (es)
EP (3) EP3341368B1 (es)
JP (3) JP6917978B2 (es)
KR (1) KR102716092B1 (es)
CN (2) CN107922413B (es)
AR (1) AR105820A1 (es)
AU (4) AU2016311295B2 (es)
BR (2) BR122023020317A2 (es)
CA (1) CA2992688A1 (es)
CL (1) CL2018000510A1 (es)
CO (1) CO2018002063A2 (es)
CY (1) CY1125359T1 (es)
DK (1) DK3341368T3 (es)
EA (1) EA201890573A1 (es)
ES (1) ES2901972T3 (es)
HR (1) HRP20211997T1 (es)
HU (1) HUE057312T2 (es)
IL (3) IL311843A (es)
LT (1) LT3341368T (es)
MA (1) MA42678B1 (es)
MD (1) MD3341368T2 (es)
MX (2) MX392554B (es)
MY (1) MY198472A (es)
NZ (2) NZ740528A (es)
PE (2) PE20221629A1 (es)
PH (2) PH12018500425B1 (es)
PL (1) PL3341368T3 (es)
PT (1) PT3341368T (es)
RS (1) RS62698B1 (es)
SG (1) SG10202003775VA (es)
SI (1) SI3341368T1 (es)
SM (1) SMT202100725T1 (es)
TN (1) TN2018000043A1 (es)
TW (3) TWI791251B (es)
WO (1) WO2017032840A1 (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI791251B (zh) * 2015-08-26 2023-02-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
US10898504B2 (en) * 2016-03-10 2021-01-26 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as PRMT5 inhibitors
CA2969295A1 (en) * 2016-06-06 2017-12-06 Pfizer Inc. Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
LT3512857T (lt) 2016-09-14 2021-04-12 Janssen Pharmaceutica Nv Menin-mll sąveikos spirobicikliniai inhibitoriai
US10611778B2 (en) 2016-09-14 2020-04-07 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of menin-MLL interaction
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
WO2018065365A1 (en) 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
EP3519413A1 (en) * 2016-10-03 2019-08-07 Janssen Pharmaceutica NV Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
MX391405B (es) 2016-12-15 2025-03-21 Janssen Pharmaceutica Nv Inhibidores de azepano de la interacción menina-mll.
GB201700526D0 (en) * 2017-01-12 2017-03-01 Univ Of Hull Therapeutic use
PE20191359A1 (es) 2017-02-27 2019-10-01 Janssen Pharmaceutica Nv Uso de biomarcadores en la identificacion de pacientes con cancer que seran sensibles al tratamiento con un inhibidor de prmt5
BR112020002736A2 (pt) 2017-08-09 2020-07-28 Prelude Therapeutics, Incorporated inibidores seletivos da proteína arginina metiltransferase 5 (prmt5)
CA3079545A1 (en) * 2017-10-26 2019-05-02 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
CA3084253A1 (en) * 2017-12-05 2019-06-13 Angex Pharmaceutical, Inc. Heterocyclic compounds as prmt5 inhibitors
MX2020005944A (es) 2017-12-08 2020-08-24 Janssen Pharmaceutica Nv Analogos espirobiciclicos novedosos.
EP3724190B1 (en) * 2017-12-13 2022-07-06 Lupin Limited Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
US10711007B2 (en) 2018-03-14 2020-07-14 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
DK3765461T3 (da) 2018-03-14 2023-11-20 Prelude Therapeutics Inc Selektive protein argininmethyltransferase 5 (prmt5)-hæmmere
WO2020033285A1 (en) * 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
MA53287A (fr) * 2018-08-07 2022-05-11 Merck Sharp & Dohme Inhibiteurs de prmt5
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3897667A4 (en) 2018-12-21 2023-04-19 Memorial Sloan Kettering Cancer Center SALICYL-ADENOSINE MONOSULFAMATE ANALOGS AND THEIR USES
CN109400545B (zh) * 2018-12-24 2022-03-25 济南大学 一种精氨酸甲基转移酶5抑制剂及其应用
CN109369507A (zh) * 2018-12-26 2019-02-22 重庆市碚圣医药科技股份有限公司 一种n-(2,2-二乙氧基乙基)邻苯二甲酰亚胺的提纯方法
WO2020168125A1 (en) * 2019-02-13 2020-08-20 Prelude Therapeutics, Incorporated Selective inhibitor of protein arginine methyltransferase 5 (prmt5)
WO2020190073A1 (ko) * 2019-03-20 2020-09-24 한국화학연구원 신규한 아졸로피리미딘 헤테로고리 화합물을 유효 성분으로 함유하는 약제학적 조성물
BR112021019125A2 (pt) * 2019-03-25 2021-11-30 1200 Pharma Llc Inibidores de prmt5 e usos dos mesmos
WO2020205867A1 (en) 2019-04-02 2020-10-08 Aligos Therapeutics, Inc. Compounds targeting prmt5
JP2022527556A (ja) * 2019-04-05 2022-06-02 プレリュード・セラピューティクス・インコーポレイテッド プロテインアルギニンメチルトランスフェラーゼ５の選択的阻害剤
US12440506B2 (en) 2019-04-05 2025-10-14 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
CA3141855A1 (en) * 2019-05-30 2020-12-03 Angex Pharmaceutical, Inc. Heterocyclic compounds as prmt5 inhibitors
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用ｐｒｍｔ５抑制劑治療癌症之方法
ES2967457T3 (es) 2019-06-10 2024-04-30 Lupin Ltd Inhibidores de PRMT5
JOP20210327A1 (ar) 2019-06-12 2023-01-30 Janssen Pharmaceutica Nv مركبات وسيطة سبيرو ثنائية الحلقة جديدة
EP4031555A1 (en) 2019-09-18 2022-07-27 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
JP2022553077A (ja) * 2019-10-21 2022-12-21 アクセント・セラピューティクス・インコーポレイテッド Ｍｅｔｔｌ３モジュレーター
US12447152B2 (en) * 2019-10-22 2025-10-21 Lupin Limited Pharmaceutical combination of PRMT5 inhibitors
GB201915447D0 (en) * 2019-10-24 2019-12-11 Johnson Matthey Plc Polymorphs of avapritinib and methods of preparing the polymorphs
EP4069698A1 (en) * 2019-12-03 2022-10-12 Lupin Limited Substituted nucleoside analogs as prmt5 inhibitors
US12441730B2 (en) 2019-12-17 2025-10-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
UA129208C2 (uk) 2019-12-19 2025-02-05 Янссен Фармацевтика Нв Заміщені спіропохідні з прямим ланцюгом
TWI883391B (zh) 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
CN115135383B (zh) 2020-02-18 2024-06-11 吉利德科学公司 抗病毒化合物
CN111233869B (zh) * 2020-03-12 2022-09-16 杭州新博思生物医药有限公司 用于制备瑞德西韦关键中间体的新化合物及其制备方法
US20220112194A1 (en) * 2020-04-01 2022-04-14 Aligos Therapeutics, Inc. Compounds targeting prmt5
US20240101589A1 (en) * 2020-10-08 2024-03-28 Strom Therapeutics Limited Inhibitors of mettl3
CN112645875A (zh) * 2020-12-09 2021-04-13 深圳海王医药科技研究院有限公司 一种盐酸丙卡特罗杂质的制备方法
JP7688152B2 (ja) 2021-04-16 2025-06-03 ギリアード サイエンシーズ， インコーポレイテッド アミドを使用してカルバヌクレオシドを調製する方法
CN113234079B (zh) * 2021-04-30 2022-02-01 上海湃隆生物科技有限公司 用作prmt5抑制剂的核苷类似物
CN117157297A (zh) * 2021-07-20 2023-12-01 上海齐鲁制药研究中心有限公司 Prmt5抑制剂
CN115703796A (zh) * 2021-08-09 2023-02-17 苏州恩泰新材料科技有限公司 一种瑞德西韦重要中间体制备方法
KR20240049311A (ko) 2021-08-18 2024-04-16 길리애드 사이언시즈, 인코포레이티드 인지질 화합물 및 이의 제조 및 사용 방법
GB202117230D0 (en) 2021-11-29 2022-01-12 Argonaut Therapeutics Ltd Peptide vaccine
GB202203588D0 (en) 2022-03-15 2022-04-27 Argonaut Therapeutics Ltd Cancer diagnostic
CN116655638B (zh) * 2022-05-12 2024-01-26 上海齐鲁制药研究中心有限公司 氘代prmt5抑制剂
CN116003339B (zh) * 2022-12-01 2024-06-28 南京师范大学 一种巨噬细胞迁移抑制因子mif双光子荧光探针及其制备方法和应用
WO2024170488A1 (en) 2023-02-13 2024-08-22 Astrazeneca Ab Prmt5 inhibitor for use in cancer therapy
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
EP4553080A1 (en) 2023-11-07 2025-05-14 Ustav Organicke Chemie a Biochemie AV CR, v.v.i. Nucleoside derivatives as antiviral agents against coronaviruses
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4224438A (en) 1970-07-14 1980-09-23 Boehringer Mannheim Gmbh Adenosine-5'-carboxylic acid amides
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
AU2002351077A1 (en) 2001-11-05 2003-05-19 Exiqon A/S Oligonucleotides modified with novel alpha-l-rna analogues
US7034147B2 (en) 2001-11-29 2006-04-25 Irm Llc Nucleoside analog libraries
RU2317994C2 (ru) * 2002-02-19 2008-02-27 Си Ви Терапьютикс, Инк. Частичные и полные агонисты аденозиновых рецепторов а1
US20040043959A1 (en) 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
US7144674B2 (en) * 2002-03-20 2006-12-05 Sumitomo Chemical Company, Limited Positive resist composition
AU2002951247A0 (en) * 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
US20060167241A1 (en) 2003-07-15 2006-07-27 Mitsui Chemicals, Inc. Method for synthesizing cyclic bisdinucleoside
EP1694642A4 (en) 2003-12-19 2010-10-06 Koronis Pharmaceuticals Inc MUTAGENIC HETEROCYCLES
EP1844062A2 (en) 2005-01-21 2007-10-17 Methylgene, Inc. Inhibitors of dna methyltransferase
WO2008001101A2 (en) 2006-06-29 2008-01-03 Astex Therapeutics Limited Pharmaceutical combinations
US20080132525A1 (en) 2006-12-04 2008-06-05 Methylgene Inc. Inhibitors of DNA Methyltransferase
AU2009298802A1 (en) 2008-09-23 2010-04-08 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
WO2011075665A2 (en) 2009-12-18 2011-06-23 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US9029343B2 (en) 2010-12-03 2015-05-12 Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof
BR112013013668A2 (pt) * 2010-12-03 2016-09-06 Epizyme Inc moduladores 7-deazapurina de histona metiltransferase, e métodos de uso dos mesmos
CN103354808B (zh) 2010-12-16 2016-08-10 Abbvie公司 抗病毒化合物
WO2012138530A1 (en) 2011-04-04 2012-10-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 2'-o-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides
WO2013062943A1 (en) 2011-10-24 2013-05-02 Glaxosmithkline Intellectual Property Development Limited New compounds
WO2013151975A1 (en) 2012-04-02 2013-10-10 Northeastern University Compositions and methods for the inhibition of methyltransferases
WO2014035140A2 (en) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
US20140100184A1 (en) 2012-08-31 2014-04-10 Baylor College Of Medicine Selective inhibitors of histone methyltransferase dot1l
CA2899363A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP2935243B1 (en) 2012-12-21 2018-03-14 Epizyme, Inc. Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
SI2935222T1 (sl) 2012-12-21 2019-02-28 Epizyme Inc. Inhibitorji PRMT5 in njihove uporabe
US8906900B2 (en) 2012-12-21 2014-12-09 Epizyme, Inc. PRMT5 inhibitors and uses thereof
EP2975938A4 (en) 2013-03-15 2017-02-15 Ohio State Innovation Foundation Inhibitors of prmt5 and methods of their use
WO2015106025A1 (en) 2014-01-09 2015-07-16 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Substituted benzoxazine and related compounds
EP3160477A4 (en) 2014-06-25 2018-07-04 Epizyme, Inc. Prmt5 inhibitors and uses thereof
PT3164130T (pt) 2014-07-01 2019-11-18 Millennium Pharm Inc Compostos de heteroaril úteis como inibidores de enzima ativadora de sumo
SG11201706050WA (en) 2015-02-24 2017-09-28 Pfizer Substituted nucleoside derivatives useful as anticancer agents
TWI791251B (zh) 2015-08-26 2023-02-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
WO2017153186A1 (en) 2016-03-10 2017-09-14 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as prmt5 inhibitors
WO2018065365A1 (en) 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
EP3519413A1 (en) * 2016-10-03 2019-08-07 Janssen Pharmaceutica NV Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
PE20191359A1 (es) 2017-02-27 2019-10-01 Janssen Pharmaceutica Nv Uso de biomarcadores en la identificacion de pacientes con cancer que seran sensibles al tratamiento con un inhibidor de prmt5
MX2020005944A (es) 2017-12-08 2020-08-24 Janssen Pharmaceutica Nv Analogos espirobiciclicos novedosos.

Also Published As

Publication number Publication date
PE20180929A1 (es) 2018-06-08
AU2016311295B2 (en) 2020-10-22
MD3341368T2 (ro) 2022-02-28
TN2018000043A1 (en) 2019-07-08
US20230330127A1 (en) 2023-10-19
AU2022215260B2 (en) 2024-04-18
CN107922413A (zh) 2018-04-17
RS62698B1 (sr) 2022-01-31
CN114057815B (zh) 2025-02-25
CA2992688A1 (en) 2017-03-02
AU2021200345A1 (en) 2021-03-18
DK3341368T3 (da) 2021-12-20
PL3341368T3 (pl) 2022-02-14
AU2024202052A1 (en) 2024-04-18
PT3341368T (pt) 2021-12-09
MA42678B1 (fr) 2021-11-30
IL311843A (en) 2024-05-01
AU2022215260A1 (en) 2022-09-01
ES2901972T3 (es) 2022-03-24
JP6917978B2 (ja) 2021-08-11
CN114057815A (zh) 2022-02-18
US20230071711A1 (en) 2023-03-09
US10653711B2 (en) 2020-05-19
EP3974428A1 (en) 2022-03-30
IL257664A (en) 2018-04-30
PH12021552054A1 (en) 2022-05-02
CN107922413B (zh) 2021-10-01
US20180243328A1 (en) 2018-08-30
AU2021200345B2 (en) 2022-08-04
LT3341368T (lt) 2021-12-10
HUE057312T2 (hu) 2022-05-28
TW202321249A (zh) 2023-06-01
EA201890573A1 (ru) 2018-07-31
IL257664B (en) 2021-05-31
KR102716092B1 (ko) 2024-10-10
US11883367B2 (en) 2024-01-30
WO2017032840A1 (en) 2017-03-02
HK1257099A1 (en) 2019-10-11
US20200360416A1 (en) 2020-11-19
JP2024012405A (ja) 2024-01-30
MX392554B (es) 2025-03-24
HRP20211997T1 (hr) 2022-04-01
JP2018528946A (ja) 2018-10-04
BR112018003595B1 (pt) 2024-03-12
CY1125359T1 (el) 2024-02-16
EP3341368A1 (en) 2018-07-04
HK1253898A1 (zh) 2019-07-05
AU2016311295A1 (en) 2018-02-08
TWI730980B (zh) 2021-06-21
JP2021169520A (ja) 2021-10-28
JP7720732B2 (ja) 2025-08-08
PH12018500425A1 (en) 2018-09-10
MY198472A (en) 2023-08-31
MX2022005182A (es) 2022-05-16
TW202146414A (zh) 2021-12-16
CO2018002063A2 (es) 2018-07-19
SG10202003775VA (en) 2020-06-29
PH12018500425B1 (en) 2022-09-02
BR122023020317A2 (pt) 2023-12-12
TW201718575A (zh) 2017-06-01
EP4219496A1 (en) 2023-08-02
TWI791251B (zh) 2023-02-01
IL282537A (en) 2021-06-30
US11318157B2 (en) 2022-05-03
EP3341368B1 (en) 2021-10-06
PE20221629A1 (es) 2022-10-19
NZ779003A (en) 2024-12-20
CL2018000510A1 (es) 2018-07-06
SMT202100725T1 (it) 2022-01-10
NZ740528A (en) 2024-11-29
KR20180041222A (ko) 2018-04-23
AR105820A1 (es) 2017-11-15
MA42678A (fr) 2021-05-19
TWI870767B (zh) 2025-01-21
BR112018003595A2 (pt) 2018-09-25
SI3341368T1 (sl) 2022-01-31

Similar Documents

Publication Publication Date Title
MX2018002326A (es) Analogos novedosos de nucleosidos sustituidos en el anillo aromatico biciclico 6-6 para su uso como inhibidores de prmt5.
MX377124B (es) Compuestos heterociclicos y usos de los mismos.
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
MX2018015709A (es) Derivados de azabencimidazol como inhibidores de pi3k beta.
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
MX2018005890A (es) Composiciones para tratar atrofia muscular espinal.
CO2017013709A2 (es) Lactamas bicíclicas.
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
MX2016014547A (es) Compuestos para tratar atrofia muscular espinal.
DOP2018000270A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
ECSP11011517A (es) Compuestos antivirales
MX376271B (es) Compuestos heterocíclicos y usos de los mismos.
GT201300174A (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme)
UY35617A (es) Inhibidores de la fosfatidilinositol 3-quinasa
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
CU20140095A7 (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY36702A (es) Piridinas sustituidas y métodos de uso
CR20130569A (es) Análogos del ácido epoxieicosatrienoicos y métodos de toma y uso del mismo
GT201400167A (es) Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2
MX2018004304A (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
CL2017001275A1 (es) Análogos ligados de urea sustituidos como moduladores de sirtuina
ECSP11010807A (es) Sales de los compuestos del inhibidor de vih
EA201791396A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
MX354015B (es) Antagonistas de trpv1 que incluyen sustituyentes dihidroxi y sus usos.